Zhejiang Kanying Import & Export Co. Ltd 86--17169758851 kanyingexport@gmail.com
Dronedarone Hydrochloride Antiarrhythmic Antibiotic API Powder 141625-93-6

Dronedarone Hydrochloride Antiarrhythmic Antibiotic API Powder 141625-93-6

  • High Light

    Dronedarone Hydrochloride powder


    Antiarrhythmic Antibiotic API Powder


    Antibiotic API Powder 141625-93-6

  • CAS
  • Molecular Formula
    C31H44N2O5S . HCl
  • The Molecular Weight
  • The Purity
  • Storage
    Cool Dry Place
  • Brand Name
    Kan Ying
  • Product Name
    Dronedarone Hydrochloride
  • The Density Of
  • Melting Point
    NA (low-melting)
  • Flash Point
  • Place of Origin
  • Brand Name
    Kan Ying
  • Minimum Order Quantity
  • Price
    To discuss
  • Packaging Details
  • Delivery Time
  • Payment Terms
    L/C, D/A, D/P, T/T, Western Union, MoneyGram,Dollars
  • Supply Ability

Dronedarone Hydrochloride Antiarrhythmic Antibiotic API Powder 141625-93-6

antiarrhythmia Spot s hair Antibiotic API inhibition Factory direct sale


1, Product title:Dronedarone hydrochloride


2, Product Description:


As an antiarrhythmic drug of Ⅲ class, zonedalone has inhibitory effect on a variety of ion channels. The results showed that 10μmol·L-1 of Deconidalone significantly reduced the delayed rectification potassium channel current of rapid activation in canine ventricular myocytes (97%, P< 0.05) and L-type calcium channel current (76.5%, P < 0.05). The same dose of finedalone can shorten the action potential dutation (APD) of Purkanye fibers. At the same time, the maximum rise rate of action potential (dV·dt-1 Max) of guinea pig ventricular myocytes was decreased by dnadalone, and the effect intensity was proportional to the concentration of dnadalone.


3, Product parameter table:



Product name Dronedarone appearance White powder
Use of the product antiarrhythmia content 99%
Molecular formula C31H44N2O5S Shelf Life 2 Years
CAS 141626-36-0 Storage Cool Dry Place


4, Use of the product:


Neldalone is an antiarrhythmic agent for patients with paroxysmal or persistent atrial fibrillation (AF) or atrial fluttering (AFL) to reduce the risk of hospitalization, patients with recent AF/AFL episodes and associated cardiovascular risk factors, and patients with sinus or reversible heart rhythm.


5, Product features:  


It can inhibit the ion channels of Na, K and Ca at the same time. It also has the antagonistic effect of B receptor. It has the antiarrhythmic effect by reducing the automaticity of the sinoatrial node, slowing down conduction velocity, prolonging the action potential duration and prolonging the QT -- QTC interval. In pharmacological studies, it was found that the electrophysiological and hemodynamic properties of finedalone were similar to amiodarone. Studies in animal models have shown that seronidalone can prevent the onset of atrial fibrillation or the recurrence of atrial fibrillation into sinus rhythm, and can prevent the onset of ventricular tachycardia and ventricular fibrillation. At present, animal experiments and partial clinical trials of this drug have been completed, and the study results show that the dosage of finedalone at 800 ms/ day in patients with atrial fibrillation is safe and effective, with few adverse reactions.


6, pharmacokinetics:


The chemical structure is similar to amiodarone, but the lipophilic property is reduced, the half-life is shortened, and the tissue accumulation of the drug is reduced. The plasma half-life of nedalone is 1 to 2 days (whereas the half-life of amiodarone is 6 to 8 weeks). The absorption rate of oral administration is 70 ~ 94%, but the absolute bioavailability of fasting oral administration is 15%. Food intake can promote the absorption, especially the fatty diet can increase the absorption of the drug by 3 ~ 4. 5 times, so it is recommended to take it after a meal. The binding rate of plasma protein was 98% and it was widely distributed in vivo. After intravenous administration, the apparent volume of distribution could reach 1 200 ~ 1 400 L. After oral administration twice a day, steady blood concentration was reached 5-7 days later. The drug is first metabolized in the liver via cytochrome P450 3A4, and its metabolite SR35021 is 3-10 times less potent than that of seronedalone. Eighty-four percent of the drug is excreted by feces and a small amount, 6 percent, is excreted by urine. In vitro studies have shown that seronedalone can penetrate the blood-brain barrier and placental barrier and can be secreted in milk.


7, Pictures of the product:


Dronedarone Hydrochloride Antiarrhythmic Antibiotic API Powder 141625-93-6 0Dronedarone Hydrochloride Antiarrhythmic Antibiotic API Powder 141625-93-6 1